Business Wire

BAXTER-INTERNATIONAL

16.10.2020 09:32:13 CEST | Business Wire | Press release

Share
Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, supports interim findings of an ongoing prospective study, “Persistent Hypermetabolism and Longitudinal Energy Expenditure in Critically Ill Patients with COVID-19 (LEEP-COVID) ,” demonstrating the role of indirect calorimetry (IC) in improving the accuracy of measuring COVID-19 patients’ nutritional needs during their intensive care unit (ICU) stay. The study, supported by Baxter through an investigator-initiated grant and recently published in Critical Care , is the first analysis of longitudinal resting energy expenditure (REE) in critically ill, mechanically ventilated COVID-19 patients. The interim findings of 22 U.S. patients assessed over 21 days suggest that predictive equations, which are commonly used to estimate patients’ nutritional needs, are largely inaccurate for this patient population. The authors observed progressive hypermetabolism and considerable variation in REE over the course of patients’ stay in the ICU, suggesting that reliance on predictive equations could lead to under-feeding of COVID-19 patients, particularly later in their ICU stay. This is notable because little is known about the nutritional needs of critically ill COVID-19 patients, and because past studies of ICU patients have associated over- and under-feeding with poor outcomes, including mortality1 .

During the study, energy needs were measured by indirect calorimetry (mREE) every third day and were compared to predicted energy needs according to the Harris-Benedict equation (HBE). Hypermetabolism and wider variability in mREE were observed after the first week in the ICU. The observed hypermetabolism persisted and mREE increased during the third ICU week with an average mREE of 150 percent of that predicted. In some cases, REE was as high as two times greater than that predicted by HBE, which significantly underpredicted REE after the first ICU week. The study’s findings align with previously published literature1,2 on the importance of measuring patients’ nutritional needs and tailoring nutrition therapy over the course of a patient’s hospitalization, as REE changes during this time.

To read the full version of the press release click here: https://www.baxter.com/baxter-newsroom/baxter-supports-new-study-showing-nutritional-needs-critically-ill-covid-19

1 Zusman et al. Resting energy expenditure, calorie and protein consumption in critically ill patients: a retrospective cohort study. Critical Care (2016) 20:367. DOI: 10.1186/s13054-016-1538-4.
2 Zusman et al. Predictive equations versus measured energy expenditure by indirect calorimetry: A retrospective validation. Clinical Nutrition (2019) Jun;38(3):1206-1210. DOI: 10.1016/j.clnu.2018.04.020. Epub 2018 May 8.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release

Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and

EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release

EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release

Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu

IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 08:00:00 CEST | Press release

As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Ga

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye